An Intensive Chemo- or Chemoimmunotherapy Regimen for Patients with Intermediate and Poor-Prognosis Acute Lymphatic Leukemia and Leukemic Lymphoblastic Lymphosarcoma: Preliminary Results with 14-Month Median Follow-Up
We previously reported the prognostic factors that can be identified at the onset of acute lymphoid leukemia (ALL) . The factors defining the prognosis are, according to our experience: the WHO Reference Center cytologic types (the “prolympho- blastic” type being always poor, the “microlymphoblastic” type good, and the “macrolymphoblastic” and the “prolymphocyte” intermediate ); the T-type is always poor, the null, as they were only characterized in our preceding protocols, intermediate ; and, in the cases of those above “intermediate” prognosis types, the volume (V) of the neoplasia plays a prognostic role, i.e., V+ (³ 104leukemic cells/mm3) and/or significant clinical masses suggest a poor prognosis .
KeywordsComplete Remission Chronic Myeloid Leukemia Cytosine Arabinoside Acute Lymphoid Leukemia Preceding Protocol
Unable to display preview. Download preview PDF.
- 2.Bernard J, Boiron M, Jacquillat C, Weil M, Najean Y (1966) Un nouvel agent actif dans le traitement des leucémies aiguës: La cytosine arabinoside. Presse Med 74:799–802Google Scholar
- 3.Florentin I, Kiger N, Bruley-Rosset M, Schulz J, Mathé G (1978) Effect of seven immunomodulators on different types of immune responses in mice. In: Serrou B, Rosenfeld C (eds) Human lymphocyte differntiation: Its application to cancer. Elsevier/North-Holland, Biomedical Press, Amsterdam, pp 299–304Google Scholar
- 4.Florentin I, Schulz J, Bruley-Rosset M, Kiger N, Mathé G (1980) In vivo immunomo- dulating properties of two synthetic agents: Azimexon and tuftsin. In: Mathé G, Muggia F (eds) Cancer chemo- and immunopharmacology. II. Immunopharmacology, relations and general problems. Springer, Berlin Heidelberg New YorkGoogle Scholar
- 5.Goutner A, Schwarzenberg L, Mathé G (1980) Phase I study of Azimexon in immunodepressed cancer patients. In: Second International Conference: Immunotherapy of cancer, present status of trials in man, Bethesda, xx April 1980Google Scholar
- 7.Mathé G, Amiel JL, Hayat M et al. (1970) Adriamycin in the treatment of acute leukemias. In: Mathé G (ed) Advances in the treatment of acute (blastic) leukemias. Springer, Berlin Heidelberg New York, pp 168–172Google Scholar
- 8.Mathé G, de Vassal F, Delgado M et al. (1976) 1975 current results of the first 100 cytologically typed acute lymphoid leukemia submitted to BCG active immunotherapy. Cancer Immunol Immunother 1:77–86Google Scholar
- 10.Mathé G, Misset JL, de Vassal.F et al. (1978) Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma and Hodgkin’s disease: Absence of crossresistance with vincristine. Cancer Treat Rep 62:805–809PubMedGoogle Scholar
- 12.Misset JL, de Vassal F, Jasmin C, Mathé G (to be published) Neuroprophylaxis in acute lymphoblastic leukemia. Correlation of neurological risk and efficacy of prevention with other prognostic factors. Eur J CancerGoogle Scholar
- 13.Schaison G, Harousseau JL, Jacquillat C, Weil M, Bernard J (1979) Phase I treatment protocol for children with increased risk acute lymphocytic leukemia (IRALL). Proc Am Assoc Cancer Res 20:104Google Scholar